Skip to main content

Table 3 Summary DLQI and pruritus VAS scores at week 16

From: Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study

Patient-reported outcome Placebo (n=88) Apremilast BID
   10 mg (n=89) 20 mg (n=86) 30 mg (n=88)
DLQI     
   Baseline 10.7 ± 6.7 10.8 ± 6.3 11.6 ± 7.0 10.6 ± 6.2
   Week 16 8.6 ± 7.6 7.6 ± 6.3 5.8 ± 6.0 6.0 ± 6.2
   Change from baseline −1.9 ± 5.2 −3.2 ± 6.0 −5.9 ± 6.7* −4.4 ± 5.1*
Pruritus VAS     
   Baseline 55.5 ± 25.5 54.1 ± 23.5 58.3 ± 26.7 55.3 ± 25.5
   Week 16 45.6 ± 30.2 39.0 ± 27.8 35.2 ± 29.2 31.6 ± 30.0
   Percent change from baseline −6.1 ± 76.4 −10.2 ± 100.8 −35.5 ± 66.0* −43.7 ± 46.8*
  1. *P≤0.005 vs placebo.
  2. Values are mean ± SD. DLQI, Dermatology Life Quality Index; VAS, visual analog scale.